[HTML][HTML] Transcriptional landscape of PTEN loss in primary prostate cancer
BMC cancer, 2021•Springer
Background PTEN is the most frequently lost tumor suppressor in primary prostate cancer
(PCa) and its loss is associated with aggressive disease. However, the transcriptional
changes associated with PTEN loss in PCa have not been described in detail. In this study,
we highlight the transcriptional changes associated with PTEN loss in PCa. Methods Using
a meta-analysis approach, we leveraged two large PCa cohorts with experimentally
validated PTEN and ERG status by Immunohistochemistry (IHC), to derive a transcriptomic …
(PCa) and its loss is associated with aggressive disease. However, the transcriptional
changes associated with PTEN loss in PCa have not been described in detail. In this study,
we highlight the transcriptional changes associated with PTEN loss in PCa. Methods Using
a meta-analysis approach, we leveraged two large PCa cohorts with experimentally
validated PTEN and ERG status by Immunohistochemistry (IHC), to derive a transcriptomic …
Background
PTEN is the most frequently lost tumor suppressor in primary prostate cancer (PCa) and its loss is associated with aggressive disease. However, the transcriptional changes associated with PTEN loss in PCa have not been described in detail. In this study, we highlight the transcriptional changes associated with PTEN loss in PCa.
Methods
Using a meta-analysis approach, we leveraged two large PCa cohorts with experimentally validated PTEN and ERG status by Immunohistochemistry (IHC), to derive a transcriptomic signature of PTEN loss, while also accounting for potential confounders due to ERG rearrangements. This signature was expanded to lncRNAs using the TCGA quantifications from the FC-R2 expression atlas.
Results
The signatures indicate a strong activation of both innate and adaptive immune systems upon PTEN loss, as well as an expected activation of cell-cycle genes. Moreover, we made use of our recently developed FC-R2 expression atlas to expand this signature to include many non-coding RNAs recently annotated by the FANTOM consortium. Highlighting potential novel lncRNAs associated with PTEN loss and PCa progression.
Conclusion
We created a PCa specific signature of the transcriptional landscape of PTEN loss that comprises both the coding and an extensive non-coding counterpart, highlighting potential new players in PCa progression. We also show that contrary to what is observed in other cancers, PTEN loss in PCa leads to increased activation of the immune system. These findings can help the development of new biomarkers and help guide therapy choices.
Springer